Knowledge graph relationships for S100A9 (292 total edges in KG)
Introduction
S100A9 S100 Calcium Binding Protein A9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
...
S100A9 Gene
Pathway Diagram
Mermaid diagram (expand to render)
Knowledge graph relationships for S100A9 (292 total edges in KG)
Introduction
S100A9 S100 Calcium Binding Protein A9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The S100A9 gene encodes Calgranulin B, also known as Myeloid-related Protein 14 (MRP14) or S100A9. Like its partner S100A8, S100A9 is a calcium-binding protein of the S100 family. S100A9 can form both homodimers and heterodimers with S100A8, with the S100A8/A9 heterodimer (calprotectin) being the biologically most active form. This protein plays critical roles in inflammation, immune defense, and more recently, in neurodegenerative diseases.
Gene Structure
The S100A9 gene is located in the S100 gene cluster on chromosome 1q21.3, adjacent to S100A8. The gene consists of 3 exons encoding a 113-amino acid protein. The promoter region contains binding sites for transcription factors including [NF-κB](/entities/nf-kb), AP-1, and C/EBP, allowing rapid induction during inflammation.
Protein Structure
The S100A9 protein contains:
EF-hand I (pseudo): N-terminal non-functional calcium-binding site
EF-hand II (canonical): C-terminal functional calcium-binding site
Hydrophobic patches: Mediate interaction with S100A8 and target proteins
C-terminal extension: Involved in dimerization and target recognition
The S100A8/A9 heterodimer (calprotectin) forms a structural basis for metal sequestration and receptor interactions.
Normal Function
S100A9, particularly as part of calprotectin (S100A8/A9), has diverse functions:
Antimicrobial defense: Withholds zinc and manganese from pathogens (nutritional immunity)
Pro-inflammatory signaling: Activates [TLR4](/entities/tlr4) and [RAGE](/genes/rage) receptors
Leukocyte recruitment: Chemotactic for neutrophils and monocytes
Oxidative stress response: Has antioxidant properties
[Apoptosis](/entities/apoptosis) regulation: Modulates intrinsic cell death pathways
Cytoskeletal dynamics: Affects neutrophil shape and movement
Expression Pattern
S100A9 is expressed in:
Neutrophils: Second most abundant cytosolic protein (40% of S100A8 amount)
Monocytes and macrophages: Induced during inflammation
Myeloid dendritic cells: At sites of immune activation
Activated [microglia](/entities/microglia): In neurodegenerative conditions
Certain epithelial cells: In inflamed tissues
Like S100A8, S100A9 expression is strongly induced by inflammatory cytokines and bacterial products.
Role in Disease
Alzheimer's Disease
S100A9 elevated in AD brain, colocalizing with amyloid plaques
Expressed by plaque-associated [microglia](/cell-types/microglia-neuroinflammation)
Contributes to neuroinflammation through:
TLR4/NF-κB pathway activation
Pro-inflammatory cytokine induction
[ROS](/entities/reactive-oxygen-species) production
Forms complexes with [Aβ](/proteins/amyloid-beta)
Detectable in CSF and plasma as biomarker
Genetic variants affect AD risk
Parkinson's Disease
Increased S100A9 in substantia nigra of PD patients
Associated with Lewy body pathology
Produced by activated microglia
Contributes to dopaminergic neuron degeneration
Correlates with disease duration and severity
Amyotrophic Lateral Sclerosis
S100A9 upregulated in ALS spinal cord
Expressed by reactive [astrocytes](/entities/astrocytes) and microglia
Contributes to motor neuron injury
Found in affected motor regions
Potential biomarker for disease progression
Multiple Sclerosis
S100A9/MSR in active MS lesions
Contributes to demyelination and axonal loss
Elevated in CSF during relapses
Predicts conversion from CIS to MS
Therapeutic target in development
Inflammatory Diseases
Rheumatoid arthritis: Biomarker of disease activity
Inflammatory bowel disease: Calprotectin standard clinical test
Calprotectin test: FDA-approved for IBD monitoring
Neurological disease: S100A8/A9 in CSF and plasma
Treatment monitoring: Levels change with therapy
Prognostic indicator: Correlates with outcomes
Key Research Directions
Receptor biology: Characterizing S100A9 receptors and signaling
Intracellular functions: Non-secreted roles in cell biology
Therapeutic targeting: Specific inhibitors and antibodies
Biomarker development: Validation in large cohorts
Genetic studies: GWAS for neurodegenerative diseases
Background
The study of S100A9 S100 Calcium Binding Protein A9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
[Update with 2025-2026 microglia research findings](/mechanisms/microglia-neuroinflammation)
[Update with 2025-2026 microglia research findings](/mechanisms/microglia-neuroinflammation)
[Update with 2025-2026 microglia research findings](/mechanisms/microglia-neuroinflammation)
[Wang S, et al, S100A8/A9 in inflammation and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31249371/)
[Foell D, et al, S100A8 and S100A9 in inflammatory diseases (2007)](https://pubmed.ncbi.nlm.nih.gov/17721636/)
[Kerkhoff C, et al, S100A8/A9: a key regulator of neutrophil function (2012)](https://pubmed.ncbi.nlm.nih.gov/22959640/)
[Lei L, et al, S100A8/A9 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32988225/)
[Horvath I, et al, S100A8/A9 as biomarker in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34185892/)
[Vogl T, et al, S100A9: from biochemistry to clinical applications (2022)](https://pubmed.ncbi.nlm.nih.gov/35018867/)
[Chang HJ, et al, Calprotectin in neurological diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34744956/)
[Austermann J, et al, S100A9: therapeutic target in inflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35679931/)
Pathway Diagram
The following diagram shows the key molecular relationships involving S100A9 - S100 Calcium Binding Protein A9 discovered through SciDEX knowledge graph analysis: